European Biotech Acquisition Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EBAC research report →
Price Chart
About the company
European Biotech Acquisition Corp. (EBAC) is presently not engaged in substantial business operations. Instead, its core purpose is to facilitate a business combination, potentially through a merger, share exchange, asset acquisition, share purchase, or reorganization, with one or more other companies or organizations.
- CEO
- Eduardo Bravo Fernandez de Araoz
- IPO
- 2021
- HQ
- Amsterdam, NL
Get TickerSpark's AI analysis on EBAC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $183.50M
- P/E
- 41.44
- PEG
- -0.79
- P/S
- 0.00
- P/B
- 1.18
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 2.90%
- ROIC
- -2.19%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-2,818,000
- Net Income
- $3.50M+136.9%
- EPS
- $0.27-37.2%
- OCF Growth
- +25.3%
- FCF Growth
- +25.3%
- 52W High
- $14.10
- 52W Low
- $9.28
- 50D MA
- $10.19
- 200D MA
- $9.97
- Beta
- 0.00
- RSI (14)
- 61
- Avg Volume
- 127.60K
No earnings-call transcripts are available for EBAC yet.
- Free Float
- 72.9%
- Shares Outstanding
- 16.40M
- Float Shares
- 11.96M
of shares held by institutions
49 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Spring Creek Capital LLC | 50.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 21 | Fazeli Mohammad Sohail | other | 0 |
| Mar 15, 21 | van de Stolpe Onno | other | 25,000 |
| Mar 15, 21 | Wegter Marcus Antonius | other | 3,400,000 |
| Mar 15, 21 | Kleijwegt Martijn | other | 3,400,000 |
| Mar 15, 21 | Kleijwegt Martijn | other | 3,400,000 |
| Mar 15, 21 | LSP Sponsor EBAC B.V. | other | 3,400,000 |
| Mar 15, 21 | Sintnicolaas Koen | other | 0 |
| Mar 15, 21 | Fernandez de Araoz Eduardo Bravo | other | 0 |
| Mar 15, 21 | Doeksen Volkert H. | other | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EBAC coverage
Recent articles, reports, and earnings notes.
No research on EBAC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EBAC report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.